Imris nets Aussie clearance for MRI, x-ray angiography technologies

TriMed Staff | | Health Exec | Precision Medicine
Image-guided therapy solutions provider IMRIS has received clearance from Australia’s Therapeutic Goods Administration allowing for the marketing of IMRISNV and IMRIScardio in Australia.

The Winnipeg, Manitoba-based company said that the IMRISNV and IMRIScardio are systems that allow for the capabilities of both MRI and x-ray angiography in a single suite without the need to transport the patient between modalities.

TriMed Staff

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Design by Adaptive Theme
Trimed Popup
Trimed Popup